Literature DB >> 20733312

Methods of outcomes measurement in nail psoriasis.

M Augustin1, A Ogilvie.   

Abstract

BACKGROUND: Nail involvement is a common feature of psoriasis, predicting higher disease severity and greater impairment in quality of life. Valid assessment of nail psoriasis is relevant for research and routine clinical use. However, no measurement standards have currently been developed.
OBJECTIVE: To identify state-of-the-art outcomes measurements in nail psoriasis by literature analysis.
METHODS: Systematic Web-based literature search, followed by structured critical appraisal and consecutive descriptive report. The search focused on methodological and epidemiological publications and papers describing outcomes of clinical trials on nail psoriasis.
RESULTS: Initially, 646 publications met the primary criteria. After non-relevant or replicate publications were excluded, 66 papers were analysed, including clinical trials or case reports (n = 41), reviews (n = 11) and methodological or epidemiological studies (n = 14). In total, 23 clinical outcomes measures and 15 patient-reported outcomes (PRO) tools were used. None had been validated according to recent standards. In the studies with clinical interventions (n = 41), NAPSI (Nail Psoriasis Severity Index; n = 4) or target NAPSI (n = 2) were the most often used single tools, followed by Physician's Global Assessment (n = 3). However, in 16 studies, no specifically described outcomes measures were used.
CONCLUSION: Valid clinical outcomes measures in nail psoriasis are rare. Existing tools lack validation and standardisation. A need exists for accurate and scientifically sound evaluation of nail psoriasis severity in trials and clinical practice. To cover all elements of nail psoriasis, the optimal nail psoriasis assessment tool would include both PRO and physician-assessed outcomes measures.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20733312     DOI: 10.1159/000316177

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  8 in total

Review 1.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

2.  Comparison of the Objective Severity and the Esthetic Perception of Nail Symptoms in Psoriasis.

Authors:  Júlia Szebényi; Péter Oláh; Rolland Gyulai
Journal:  Skin Appendage Disord       Date:  2022-02-14

3.  Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features.

Authors:  Karen Regina Rosso Schons; André Avelino Costa Beber; Maristela de Oliveira Beck; Odirlei André Monticielo
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

4.  Nail psoriasis as a severity indicator: results from the PsoReal study.

Authors:  Marc A Radtke; Anna K Langenbruch; Ines Schäfer; Katharina Herberger; Kristian Reich; Matthias Augustin
Journal:  Patient Relat Outcome Meas       Date:  2010-12-22

Review 5.  Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease.

Authors:  Trinh Hermanns-Lê; Enzo Berardesca; Gérald E Piérard; Marianne Lesuisse; Claudine Piérard-Franchimont
Journal:  J Biomed Biotechnol       Date:  2012-08-13

Review 6.  Oral fumaric acid esters for psoriasis.

Authors:  Ausama Atwan; John R Ingram; Rachel Abbott; Mark J Kelson; Timothy Pickles; Andrea Bauer; Vincent Piguet
Journal:  Cochrane Database Syst Rev       Date:  2015-08-10

Review 7.  Nail psoriasis: a review of the literature.

Authors:  Karen Regina Rosso Schons; Cristiane Faccin Knob; Nádia Murussi; André Avelino Costa Beber; Walter Neumaier; Odirlei André Monticielo
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

8.  Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments.

Authors:  Christine Blome; Matthias Augustin; Toni Maria Klein
Journal:  Am J Clin Dermatol       Date:  2021-08-12       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.